BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Savitt D, Jankovic J. Tardive syndromes. Journal of the Neurological Sciences 2018;389:35-42. [DOI: 10.1016/j.jns.2018.02.005] [Cited by in Crossref: 42] [Cited by in F6Publishing: 31] [Article Influence: 10.5] [Reference Citation Analysis]
Number Citing Articles
1 Bashir HH, Jankovic J. Treatment of Tardive Dyskinesia. Neurologic Clinics 2020;38:379-96. [DOI: 10.1016/j.ncl.2020.01.004] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
2 Frei K, Truong DD, Fahn S, Jankovic J, Hauser RA. The nosology of tardive syndromes. Journal of the Neurological Sciences 2018;389:10-6. [DOI: 10.1016/j.jns.2018.02.008] [Cited by in Crossref: 34] [Cited by in F6Publishing: 24] [Article Influence: 8.5] [Reference Citation Analysis]
3 DʼArrigo AM, Campiglio L, Casellato C, Gambini C, Belvedere D, Secchi M, Rosci C, Priori A. Tardive Myoclonic Dyskinesia Responsive to Sodium Oxybate. Clin Neuropharmacol 2018;41:194-6. [PMID: 29927806 DOI: 10.1097/WNF.0000000000000290] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
4 Blackburn J, Parnes M. Tics, tremors and other movement disorders in childhood. Curr Probl Pediatr Adolesc Health Care 2021;51:100983. [PMID: 33832853 DOI: 10.1016/j.cppeds.2021.100983] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Orlova YY, Mehla S, Chua AL. Drug Safety in Episodic Migraine Management in Adults Part 1: Acute Treatments. Curr Pain Headache Rep 2022. [PMID: 35536501 DOI: 10.1007/s11916-022-01057-3] [Reference Citation Analysis]
6 Duma SR, Fung VS. Drug-induced movement disorders. Aust Prescr 2019;42:56-61. [PMID: 31048939 DOI: 10.18773/austprescr.2019.014] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 4.7] [Reference Citation Analysis]
7 Ueno K, Misaki M, Omori I, Kosaka H. A new approach for the diagnosis of respiratory dyskinesia using chest and abdominal band sensors. Psychiatry Clin Neurosci 2021;75:295-6. [PMID: 34164886 DOI: 10.1111/pcn.13281] [Reference Citation Analysis]
8 Truong DD, Frei K. Setting the record straight: The nosology of tardive syndromes. Parkinsonism & Related Disorders 2019;59:146-50. [DOI: 10.1016/j.parkreldis.2018.11.025] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
9 Ayyagari R, Goldschmidt D, Zhou M, Ribalov R, Caroff SN, Leo S. Defining utility values for patients with tardive dyskinesia. Curr Med Res Opin 2022;:1-25. [PMID: 35045768 DOI: 10.1080/03007995.2021.2022918] [Reference Citation Analysis]
10 Morton RO, Morton LC, Fedora R. Recognition and Treatment of Tardive Dyskinesia in Individuals with Intellectual Disability. Case Rep Psychiatry 2020;2020:8886980. [PMID: 33414976 DOI: 10.1155/2020/8886980] [Reference Citation Analysis]
11 Hauser RA, Meyer JM, Factor SA, Comella CL, Tanner CM, Xavier RM, Caroff SN, Lundt L. Differentiating tardive dyskinesia: a video-based review of antipsychotic-induced movement disorders in clinical practice. CNS Spectr . [DOI: 10.1017/s109285292000200x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 2.5] [Reference Citation Analysis]
12 Berry AJ. Acute dyskinesia in a patient with schizophrenia. BMJ Case Rep 2018;11:e225251. [PMID: 30567212 DOI: 10.1136/bcr-2018-225251] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
13 Sajatovic M, Finkbeiner S, Wilhelm A, Barkay H, Chaijale N, Gross N, Gordon MF. Long-Term Safety and Efficacy of Deutetrabenazine in Younger and Older Patients With Tardive Dyskinesia. Am J Geriatr Psychiatry 2021:S1064-7481(21)00424-3. [PMID: 34511333 DOI: 10.1016/j.jagp.2021.08.003] [Reference Citation Analysis]
14 Patterson-Lomba O, Ayyagari R, Carroll B. Risk assessment and prediction of TD incidence in psychiatric patients taking concomitant antipsychotics: a retrospective data analysis. BMC Neurol 2019;19:174. [PMID: 31325958 DOI: 10.1186/s12883-019-1385-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
15 Méneret A, Garcin B, Frismand S, Lannuzel A, Mariani LL, Roze E. Treatable Hyperkinetic Movement Disorders Not to Be Missed. Front Neurol 2021;12:659805. [PMID: 34925200 DOI: 10.3389/fneur.2021.659805] [Reference Citation Analysis]
16 Hauser RA, Truong D. Tardive dyskinesia: Out of the shadows. J Neurol Sci 2018;389:1-3. [PMID: 29449008 DOI: 10.1016/j.jns.2018.02.009] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 3.3] [Reference Citation Analysis]
17 Bhidayasiri R, Kane JM, Frei KP, Caroff SN, Correll CU, Fahn S, Jankovic J, Hauser RA, Truong DD. Expanding phenomenologic heterogeneity of tardive syndromes: Time for an updated assessment tool. Parkinsonism Relat Disord 2020;77:141-5. [PMID: 32823151 DOI: 10.1016/j.parkreldis.2020.06.023] [Reference Citation Analysis]
18 Claassen DO, Philbin M, Carroll B. Deutetrabenazine for tardive dyskinesia and chorea associated with Huntington's disease: a review of clinical trial data. Expert Opin Pharmacother 2019;20:2209-21. [PMID: 31613641 DOI: 10.1080/14656566.2019.1674281] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
19 Niemann N, Jankovic J. Treatment of Tardive Dyskinesia: A General Overview with Focus on the Vesicular Monoamine Transporter 2 Inhibitors. Drugs 2018;78:525-41. [PMID: 29484607 DOI: 10.1007/s40265-018-0874-x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 7.0] [Reference Citation Analysis]
20 Bellows S, Jankovic J. Parkinsonism and tremor syndromes. J Neurol Sci 2021;:120018. [PMID: 34686357 DOI: 10.1016/j.jns.2021.120018] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
21 Colucci F, Carvalho V, Gonzalez-Robles C, Bhatia KP, Mulroy E. From Collar to Coccyx: Truncal Movement Disorders: A Clinical Review. Mov Disord Clin Pract 2021;8:1027-33. [PMID: 34631937 DOI: 10.1002/mdc3.13325] [Reference Citation Analysis]
22 Chen CY, Chiang HL, Fuh JL. Tardive syndrome: An update and mini-review from the perspective of phenomenology. J Chin Med Assoc 2020;83:1059-65. [PMID: 32956105 DOI: 10.1097/JCMA.0000000000000435] [Reference Citation Analysis]
23 Hasnain N, Arif TB, Shafaut R, Zakaria F, Fatima SZ, Haque IU. Association between sex and Huntington's disease: an updated review on symptomatology and prognosis of neurodegenerative disorders. Wien Med Wochenschr 2022. [PMID: 35723821 DOI: 10.1007/s10354-022-00941-2] [Reference Citation Analysis]
24 Factor SA, Burkhard PR, Caroff S, Friedman JH, Marras C, Tinazzi M, Comella CL. Recent developments in drug-induced movement disorders: a mixed picture. Lancet Neurol 2019;18:880-90. [PMID: 31279747 DOI: 10.1016/S1474-4422(19)30152-8] [Cited by in Crossref: 26] [Cited by in F6Publishing: 10] [Article Influence: 8.7] [Reference Citation Analysis]
25 Selçuk M. Tardive Myoclonus Responsive to Clozapine Misdiagnosed as Restless Leg Syndrome: A Case Report. J Clin Psychopharmacol 2021;41:692-4. [PMID: 34459435 DOI: 10.1097/JCP.0000000000001463] [Reference Citation Analysis]
26 Dorfman BJ, Jimenez-Shahed J. Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia. Expert Rev Neurother 2021;21:9-20. [PMID: 33174440 DOI: 10.1080/14737175.2021.1848548] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
27 Factor SA. Management of Tardive Syndrome: Medications and Surgical Treatments. Neurotherapeutics 2020;17:1694-712. [PMID: 32720245 DOI: 10.1007/s13311-020-00898-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
28 Hull M, Parnes M, Jankovic J. Botulinum Neurotoxin Injections in Childhood Opisthotonus. Toxins (Basel) 2021;13:137. [PMID: 33673369 DOI: 10.3390/toxins13020137] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
29 Warren B, Vanderhoef D, Johnson J. VMAT2 Inhibitors for the Treatment of Tardive Dyskinesia. Issues Ment Health Nurs 2021;:1-10. [PMID: 34370608 DOI: 10.1080/01612840.2021.1948643] [Reference Citation Analysis]
30 Ward KM, Citrome L. Antipsychotic-Related Movement Disorders: Drug-Induced Parkinsonism vs. Tardive Dyskinesia-Key Differences in Pathophysiology and Clinical Management. Neurol Ther 2018;7:233-48. [PMID: 30027457 DOI: 10.1007/s40120-018-0105-0] [Cited by in Crossref: 25] [Cited by in F6Publishing: 15] [Article Influence: 6.3] [Reference Citation Analysis]
31 Vijayakumar D, Jankovic J. Medical treatment of blepharospasm. Expert Review of Ophthalmology 2018;13:233-43. [DOI: 10.1080/17469899.2018.1503535] [Cited by in Crossref: 2] [Article Influence: 0.5] [Reference Citation Analysis]
32 Baizabal-Carvallo JF, Jankovic J. The clinical phenomenology and correlations of oculogyric tics. Acta Neurol Belg 2022. [PMID: 35397742 DOI: 10.1007/s13760-022-01944-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
33 Palermo G, Mazzucchi S, Unti E, Bonuccelli U, Ceravolo R. Tardive Syndrome Associated With Tetrabenazine in Huntington Disease: A Case Report. J Clin Psychopharmacol 2020;40:628-30. [PMID: 33136925 DOI: 10.1097/JCP.0000000000001295] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
34 Margolesky J. Approaching drug-induced parkinsonism from a neurohospitalist perspective. Expert Review of Neurotherapeutics 2019;19:93-5. [DOI: 10.1080/14737175.2019.1569515] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
35 Margolius A, Fernandez HH. Current treatment of tardive dyskinesia. Parkinsonism Relat Disord 2019;59:155-60. [PMID: 30591350 DOI: 10.1016/j.parkreldis.2018.12.022] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
36 Tripathi R, Reich SG, Scorr L, Guardiani E, Factor SA. Lurasidone-Induced Tardive Syndrome. Mov Disord Clin Pract 2019;6:601-4. [PMID: 31538095 DOI: 10.1002/mdc3.12812] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
37 Niemann N, Jimenez-Shahed J. Deutetrabenazine in the treatment of tardive dyskinesia. Neurodegener Dis Manag 2019;9:59-71. [PMID: 30702019 DOI: 10.2217/nmt-2018-0042] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
38 Meoni S, Macerollo A, Moro E. Sex differences in movement disorders. Nat Rev Neurol 2020;16:84-96. [PMID: 31900464 DOI: 10.1038/s41582-019-0294-x] [Cited by in Crossref: 34] [Cited by in F6Publishing: 28] [Article Influence: 17.0] [Reference Citation Analysis]
39 Bologna M, Valls-Solè J, Kamble N, Pal PK, Conte A, Guerra A, Belvisi D, Berardelli A. Dystonia, chorea, hemiballismus and other dyskinesias. Clin Neurophysiol 2022;140:110-25. [PMID: 35785630 DOI: 10.1016/j.clinph.2022.05.014] [Reference Citation Analysis]
40 Ruparelia P, Pandya U, Gill N, Verma O. Restless tongue: Lingual Tardive Dyskinesia - A rare case report. J Oral Biol Craniofac Res 2022;12:99-101. [PMID: 34820254 DOI: 10.1016/j.jobcr.2021.10.006] [Reference Citation Analysis]
41 Poyurovsky M, Weizman A. Treatment of Antipsychotic-Induced Akathisia: Role of Serotonin 5-HT2a Receptor Antagonists. Drugs 2020;80:871-82. [PMID: 32385739 DOI: 10.1007/s40265-020-01312-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
42 González-rodríguez A, Labad J, Seeman MV. Pain Sensitivity in Schizophrenia Spectrum Disorders: A Narrative Review of Recent Work. Psychiatry International 2021;2:48-58. [DOI: 10.3390/psychiatryint2010004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
43 Baumgärtner J, Grohmann R, Bleich S, Glocker C, Seifert J, Toto S, Rüther E, Engel RR, Stübner S. Atypical dyskinesias under treatment with antipsychotic drugs: Report from the AMSP multicenter drug safety project. World J Biol Psychiatry 2021;:1-14. [PMID: 34096837 DOI: 10.1080/15622975.2021.1938213] [Reference Citation Analysis]
44 Demyttenaere K, Detraux J, Racagni G, Vansteelandt K. Medication-Induced Akathisia with Newly Approved Antipsychotics in Patients with a Severe Mental Illness: A Systematic Review and Meta-Analysis. CNS Drugs 2019;33:549-66. [DOI: 10.1007/s40263-019-00625-3] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 4.3] [Reference Citation Analysis]
45 Prasad S, Pal PK. Levodopa-Associated Barking Vocalizations. J Mov Disord 2021;14:164-5. [PMID: 33121222 DOI: 10.14802/jmd.20086] [Reference Citation Analysis]